Commure vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
$200M funding 2025; $200M+ ARR (doubled 3 consecutive years); $6B valuation (merged Athelas); 130+ health systems; HCA partnership; acquired Augmedix $139M/Memora; healthcare RCM leader
About
Commure is a healthcare infrastructure company founded to modernize the operational and clinical technology layer of health systems, which have historically relied on fragmented, decades-old software systems for workflows ranging from patient communication to revenue cycle management. The company was co-founded by Tanay Tandon and emerged from General Catalyst's health system subsidiary model, which provides capital and technology directly to large hospital networks. Commure merged with Athelas — an AI-powered revenue cycle management company — in 2023, combining Athelas's proven RCM automation with Commure's broader health system workflow platform to create a more comprehensive enterprise offering.\n\nCommure's platform addresses operational challenges across the health system enterprise including clinical documentation, ambient AI scribing through its Commure Scribe product, revenue cycle automation, patient engagement, and care team communication. The acquisition of Augmedix in 2024 added a leading ambient clinical intelligence capability, enabling physicians to automatically generate clinical notes from patient encounters using AI. Commure serves 130+ health systems and counts HCA Healthcare — one of the largest for-profit hospital networks in the US — as a strategic partner, providing both market validation and scale distribution for its products.\n\nCommure has achieved $200 million+ in annual recurring revenue, doubling for three consecutive years — a growth trajectory that has pushed its valuation to approximately $6 billion. The company's model of embedding deeply within health system operations, rather than selling point solutions that compete at the application layer, creates high switching costs and durable revenue streams. As health systems face intensifying margin pressure and clinician burnout driven by administrative overhead, Commure's AI-driven automation of clinical and operational workflows addresses two of the most urgent priorities simultaneously.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.